Figure 7.

IgG 3–43 inhibits growth of a subcutaneous xenograft FaDu tumor model in SCID mice. Mice were treated when tumors reached a size of ∼100 mm³ (2 weekly injections for 3 weeks, see lines) with the indicated doses. (a-d) Growths of individual tumors in mice treated with PBS (a), 30 µg IgG 3–43 (b), 100 µg IgG 3–43 (c), or 300 µg IgG 3–43 (d). (e) Kaplan-Meier plot of survival. (f) Tumor volumes at day 42. (g) Pharmacokinetics of IgG 3–43. Serum concentrations of IgG 3–43 were determined by ELISA after the first intravenous injection (day 14) and last intravenous injection (day 31) of treatment at the indicated doses. (h) Body weight of animals during treatment.